Lu sur :https://www.ncbi.nlm.nih.gov/pubmed/29090020
[ligne][/ligne]
Traduction disponible directement en cliquant en bas à droite de ce message sur notre forum
[ligne][/ligne]
Long-term treatment of refractory myasthenia gravis with subcutaneous immunoglobulin.
Kovács E1, Dankó K2, Nagy-Vince M2, Csiba L1, Boczán J3.
Ther Adv Neurol Disord. 2017 Nov;10(11):363-366. doi: 10.1177/1756285617722437. Epub 2017 Jul 26.
Myasthenia gravis (MG) is an autoimmune disease characterized by fatigue and weakness of skeletal muscles.
Laryngeal myasthenia (when dysphonia is the initial and primary complaint) is a rare variant of MG (0.46%),1 which may provide a diagnostic challenge.
Although with adequate treatment majority of myasthenic patients can live productive lives with no or few symptoms, there is a distinct subset of patients who have a very difficult-to-control disease.
Here we report two cases of treatment-refractory patients (one generalized and one initially isolated laryngeal MG) successfully managed by long-term application of subcutaneous immunoglobulin (SCIG).
Message d' un membre de l'équipe technique |
Nous utilisons un service automatique de traduction fourni par YANDEX. Soyez vigilant sur le risque de contre-sens inhérent à ce genre d'outils. |
L’article étant gratuit, voici le lien vers la traduction directe en français via Google traduction
https://translate.google.fr/translate?h ... &sandbox=1